# Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease

## TL;DR

A 62-year-old woman with a persistent pituitary tumor found relief with pasireotide after traditional treatments failed.

## Contribution

This case highlights pasireotide as a promising treatment for resistant pituitary adenomas.

## Key findings

- Pasireotide stabilized the tumor mass over 6 months.
- The patient's symptoms, including headaches, disappeared after treatment.
- Pasireotide may offer a new therapeutic option for treatment-resistant pituitary adenomas.

## Abstract

A 62-year-old Sudanese female was diagnosed with a nonfunctioning pituitary adenoma in 2006. Despite undergoing 3 transsphenoidal surgeries and radiotherapy, her tumor persisted, causing debilitating symptoms, including headaches and visual defects. As a last resort, she was treated with pasireotide, a second-generation somatostatin analog with a broader receptor affinity than first-generation drugs. Over 6 months, the tumor mass was stabilized, and her symptoms, including headaches, disappeared. This case demonstrates a potential new therapeutic possibility for treating resistant pituitary adenoma with pasireotide, offering hope for patients when traditional treatments fail.